Navigation Links
Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere's Disease
Date:12/11/2013

hair of the department of otolaryngology – head and neck surgery at Medical University of South Carolina, and clinical investigator for the Phase 2b clinical trial, "Unpredictable spontaneous vertigo is life altering and a source of considerable distress for patients with Meniere's disease, and there are currently no FDA-approved drug therapies. This study may bring us closer to providing a safe and effective treatment option for the many patients with this debilitating disorder."

The study will also assess the safety and tolerability of OTO-104, which is a proprietary, sustained-exposure otic formulation of dexamethasone. Upon screening, all subjects will enter into a 4-week observational period for a baseline assessment during which subjects will record their vertigo and tinnitus symptoms via a daily diary. Following the lead-in period, eligible subjects will be randomized 1:1 to a single intratympanic injection of 12 mg OTO-104 or placebo (gel vehicle). Tinnitus will also be assessed as a secondary endpoint in the study.

Additional information about study protocol and enrollment sites for the study can be found at www.clinicaltrials.gov using the study identifier NCT01412177.

About OTO-104
OTO-104 is a sustained-exposure formulation of the steroid dexamethasone that has been designed for intratympanic (IT) injection into the middle ear for the potential treatment of a broad range of inner ear disorders including vertigo and acute onset hearing loss. OTO-104 is based on Otonomy's proprietary formulation technology which is intended to overcome the limitations associated with the use of unapproved short-acting solutions in the ear. These include limited and variable drug exposure, need for repeat IT injections, and potential for suboptimal efficacy. OTO-104 successfully completed a Phase 1b trial in Meniere's disease patients that demonstrated a clinically meaningful reduction in vertigo f
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Otonomy Completes $45.9 Million Series C Equity Financing
2. Otonomy Acquires Assets and Patent Rights for Tinnitus Program
3. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
4. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
5. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
6. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
7. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
8. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
9. Barts Hospital, London enrolls first patients in ROX Medicals CONTROL-HTN resistant hypertension trial
10. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... ENGLEWOOD, Colo. , Sept. 22, 2014 ... one of the U.S. commercial launch of its foot ... distributed by Paragon 28.  The GORILLA TM R3CON ... 28, joining the Monster TM & Mini-Monster TM ... Systems. Comprised of 10 interchangeable subsystems, the ...
(Date:9/22/2014)... , September 22, 2014 ... has announced the addition of the  "Global ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... to wirelessly operate electronic gadgets such as ... consoles from a short line-of-sight distance. Remote ...
(Date:9/22/2014)... 22, 2014 Final shortlist ...   The second edition of the much-awaited VCCircle ... to announce the final nominations for the 2014 honours. ... the evening of September 25 at The Taj Mahal Palace, ... based on a variety of qualitative and quantitative parameters ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2Global Remotes Market 2014-2018 2Global Remotes Market 2014-2018 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3
... The Pharmaceutical Care Management Association (PCMA) issued the ... hearing: "The independent drugstore lobby continues ... for themselves in Medicaid while demanding more transparency for ... and retail pharmacy allies in the embarrassing role of ...
... Oxford Finance Corporation (Oxford), a subsidiary of ... Debbie Baker to its Business Development group. As director, ... for life science and medical device companies, primarily in ... 30 years of financial experience, predominantly with the healthcare ...
Cached Medicine Technology:PCMA: Independent Drugstore Lobby Continues 'Disclosure Double Standard' Transparency Campaign 2Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America 2
(Date:9/22/2014)... Rockville Centre, NY (PRWEB) September 22, 2014 ... Goodwin, before whom all of the federal mesh ... Boston Scientific Corp. have been consolidated for pretrial ... re: Boston Scientific Corp. Pelvic Repair System Products ... Southern District of West Virginia; Case no. 2:12-md-02326)—requiring ...
(Date:9/22/2014)... News) -- Teens and young adults at risk for ... help prevent risky sexual behaviors, according to new recommendations ... year, about 20 million new sexually transmitted infections such ... About half involve people between 15 and 24 years ... new report, published Sept. 22 in Annals of ...
(Date:9/22/2014)... September 22, 2014 Manhattan residents who ... side of the hip , which could be bursitis ... This treatment is now offered at New York Dynamic ... called trochanteric bursitis, occurs when the trochanteric bursa becomes ... in the hip, between the iliotibial band and the ...
(Date:9/22/2014)... to 40 percent of patients undergoing breast cancer surgery ... all the cancerous tissue in the initial operation. However, ... tested a tool they developed that will help surgeons ... decreasing the chances for repeat operations. ... September 22, 2014 in the Proceedings of the ...
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
Breaking Medicine News(10 mins):Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:The fine line between breast cancer and normal tissues 2Health News:Higher risk of heart disease for South Asians in Canada 2
... 19 /PRNewswire-FirstCall/ - Notification of Year End,2007 Earnings Webcast ... (TSX: RBM) Year End 2007 Earnings Webcast and ... To listen to this Webcast and Conference Call ... To participate in the live conference call please dial ...
... Using the Canadian Light Source synchrotron, an international team led ... detailed structure of the enzyme the Norwalk virus uses to ... itself. The information is crucial to developing drugs that could ... viruses. , The Norwalk virus uses the enzyme, RNA ...
... (OTC,Bulletin Board: RXEI), a developer, manufacturer, and marketer of ... its,2007 year-end financial results in a conference call on ... Company will release its 2007 year-end financial results after ... call will be,RxElite CEO Jonathan Houssian, COO Earl E. ...
... ST. LOUIS, March 18 Sigma-Aldrich (Nasdaq:,SIAL) announced ... its $300 million,revolving credit facility established in December ... feature. Under the revised $450 million,revolving credit facility, ... and,$420 million will mature on December 11, 2012. ...
... The Pharmaceutical Care,Management Association (PCMA) issued the ... that are being,debated in Congress:, "PCMA ... drug,therapies is an important tool in promoting ... way with Pharmacy & Therapeutics,(P&T) committees and ...
... mental acuity may actually improve , , TUESDAY, March 18 ... treatment, head-and-neck cancer patients experience decreases in their physical ... quality of life, says a U.S. study. , ... that head and neck cancer treatment such as feeding ...
Cached Medicine News:Health News:Scientists see Norwalk virus' Achilles heel 2Health News:RxElite Inc. Fourth Quarter and Year-End 2007 Earnings Release and Conference Call Notice 2Health News:Head and Neck Cancer Outcomes a Mixed Bag 2
... The new Amsco 3080/3085 SP Bariatric ... width capacity and expanded surgical capabilities for ... extensions are rated for patients up to ... and easy attachment and full positioning capability. ...
... The new Amsco 3080/3085 SP Bariatric Foot ... capacity and expanded surgical capabilities for Amsco ... The Amsco Foot Extension is rated for ... designed for secure and easy attachment and ...
... The Pulsavac Plus System offers a ... Debridement System. High power efficiently clears bone ... Specific tips are available for hip and ... a wide range of pressure options for ...
The Simpulse Solo Pulsed Lavage System requires minimal set up and has a Wide range of tips available for every orthopaedic procedure. It uses a separate suction lumen to reduce clogging and n ergono...
Medicine Products: